Assertio completes merger with Zydus Lifesciences at $23.5 per share cash

Assertio Holdings, Inc.

Assertio Holdings, Inc.

ASRT

0.00
  • Zydus Lifesciences completed its acquisition of Assertio, taking the drugmaker private and delisting its Nasdaq-listed shares.
  • Assertio shareholders will receive USD 23.5 per share in cash under the merger terms.
  • The deal triggered a fundamental change for Assertio’s outstanding 6.50% Convertible Senior Notes due 2027, with cash repurchase set for July 17.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606161630BIZWIRE_USPR_____20260616_BW901266) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.